Gilead and it’s investors are going to be upset

Gilead and it’s investors are going to be upset in 5 years when Leronlimab is the standard for mono and combo. Gilead’s current combination drug in phase 1 will have little, if any, market to penetrate (if it’s approved). The approval of leronlimab for mono therapy, when the trial is complete, is going to blow the top of the HIV market. Gilead still has an opportunity to license Leronlimab and it’s possible they’re one of the BPs attempting to license the drug as I write this.